Companies Dominating the Ocular Drug Delivery Devices Landscape
- Bausch Health Companies Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Taiwan Liposome Company, Ltd.
- Ocular Therapeutix, Inc.
- Kiora Pharmaceuticals, Inc.
- Graybug Vision Inc.
- Apellis Pharmaceuticals, Inc.
- Implanet Company
- Aerie Pharmaceuticals Inc.
- EyePoint Pharmaceuticals, Inc.
- Protalix BioTherapeutics
Browse Key Market Insights with Data Illustration:
In the News
-
EyePoint Pharmaceuticals, Inc. announced the interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD.
-
EyeGate Pharmaceuticals, Inc. announced the first successful dosage of its drug PP-001 in the phase II proof-of-concept (“POC”) study of ocular surface inflammation. PP-001 is an inhibitor of dihydroorotate dehydrogenase
